Cipher Pharmaceuticals Inc  

(Public, TSE:CPH)   Watch this stock  
Find more results for TSE:DND
+0.01 (0.18%)
Feb 5 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 5.46 - 5.73
52 week 4.77 - 17.50
Open 5.73
Vol / Avg. 19,689.00/32,417.00
Mkt cap 143.29M
P/E 37.44
Div/yield     -
EPS 0.15
Shares 26.04M
Beta 0.59
Inst. own     -
Feb 23, 2016
Q4 2015 Cipher Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Dec 2, 2015
Cipher Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -26.19% 63.96%
Operating margin -25.72% 61.27%
EBITD margin - 67.80%
Return on average assets -8.49% 31.61%
Return on average equity -17.01% 41.33%
Employees 13 -
CDP Score - -


2345 Argentia Road, Suite 100A
+1-905-6025840 (Phone)
+1-905-6020628 (Fax)

Website links


Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company focused on dermatology. The Company acquires products that fulfill medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly or through partners. The Company's dermatology products include Sitavig, Absorica, Epuris, Beteflam, Dermadexin, Pruridexin, Ozenoxacin, CF101, ASF-1096 and Nanolipolee-007. The Company's other products include Lipofen, Conzip and Durela.

Officers and directors

Gerald P. McDole Independent Chairman of the Board
Age: 75
Shawn Patrick O'Brien President, Chief Executive Officer
Norman C. Evans Chief Financial Officer, Secretary
Age: 60
Joan Chypyha President, General Manager - Canada
Joseph Pecora President and General Manager - USA
Lorne Markowitz Vice President of Sales and Marketing
Linda Melanie Angaritis Vice President - Global Regulatory Compliance and Quality
Louise Blythe Vice President - Regulatory Affairs
Lynne Bulger Vice President - Medical and Clinical Affairs
Brian Rosenberger Vice President - Alliance and Strategic Portfolio Management